FD-005

FD-005 is a degrader antibody conjugate (DAC) targeting CD33, currently in the discovery phase of development by Chengdu FenDi Pharmaceutical. As a DAC, FD-005 represents a novel therapeutic modality that combines the precise targeting of a monoclonal antibody with the potent mechanism of targeted protein degradation (TPD). The antibody component is designed to bind to CD33, a cell surface antigen predominantly expressed on myeloid cells and frequently overexpressed in acute myeloid leukemia (AML). Upon binding and internalization into the target cell, the degrader payload—typically a PROTAC or molecular glue—is released to facilitate the ubiquitination and subsequent proteasomal degradation of a specific target protein. This catalytic approach to protein knockdown is intended to provide superior efficacy and overcome resistance mechanisms associated with traditional antibody-drug conjugates (ADCs).